&nbsp;

brad-campbell.jpg

Jan 2023

Regimen

PACL+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

PACL(W)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Regimen

PACL(DD)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Document

PEBCBiodegradableRectalSpacersforProstateCancerRadiotherapy.pdf

Mar 2023

Document

PolicyRectalSpacersImplementationGuidanceDocumentProstateCancerPatientsOntario.pdf

Mar 2023

Document

PolicySpecialAccessProgramRectalSpacers.pdf

Mar 2023

Document

PolicySpecialAccessProgramRectalSpacersResubmissionAppeals.pdf

Mar 2023

Programme de financement des traitements à coût élevé

Le Programme de financement des traitements à coût élevé finance principalement les médicaments anticancéreux injectables ou oraux onéreux...

Regimen

BELZ

Cancer Type:

Endocrine,

Pancreatic Neuroendocrine,

Genitourinary,

Renal cell / Kidney

Intent: Curative, Palliative

Funding:

Exceptional Access Program

Belzutifan – For the treatment of adult patients with von Hippel-Lindau (VHL) disease, based on criteria

Drugs Used:

belzutifan